(CYTK) Cytokinetics - Ratings and Ratios
Cardiac Activator, Skeletal Activator, Cardiac Inhibitor
CYTK EPS (Earnings per Share)
CYTK Revenue
Description: CYTK Cytokinetics November 05, 2025
Cytokinetics Inc. (NASDAQ:CYTK) is a late-stage biotech that designs small-molecule muscle activators and inhibitors to treat serious U.S. diseases. Its lead programs are omecamtiv mecarbil (a cardiac myosin activator in Phase III for heart failure), CK-089 (a fast skeletal muscle troponin activator in Phase I), CK-586 (a cardiac myosin inhibitor in Phase II), and aficamten (an oral cardiac myosin inhibitor in Phase III for hypertrophic cardiomyopathy). The company also holds a strategic alliance with Ji Xing Pharmaceuticals for aficamten’s development and commercialization in Japan.
As of the latest quarterly filing, Cytokinetics reported a cash runway of roughly $250 million, supporting its R&D spend of about $120 million year-to-date. The Phase III GALACTIC-HF trial for omecamtiv mecarbil is slated for data readout in Q2 2026, while aficamten’s Phase III trial (EXPLORER-HCM) expects results by early 2025. The firm’s market capitalization hovers near $1.3 billion, reflecting investor weighting of these late-stage assets.
The cardiovascular biotech sector is being driven by an aging U.S. population and the expanding prevalence of heart failure, projected to affect over 6 million Americans by 2030. Concurrently, the biotech funding environment remains favorable, with venture capital allocating roughly $30 billion annually to early-stage therapeutics, but late-stage companies like CYTK must demonstrate clear regulatory milestones to sustain valuation.
For a deeper, data-rich perspective on CYTK’s risk-adjusted upside, you may find it worthwhile to explore the analyst tools on ValueRay.
CYTK Stock Overview
| Market Cap in USD | 7,609m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2004-04-29 |
CYTK Stock Ratings
| Growth Rating | 38.0% |
| Fundamental | 32.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -5.35% |
| Analyst Rating | 4.29 of 5 |
CYTK Dividends
Currently no dividends paidCYTK Growth Ratios
| Growth Correlation 3m | 88.5% |
| Growth Correlation 12m | -6.1% |
| Growth Correlation 5y | 58.7% |
| CAGR 5y | 18.24% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.25 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.46 |
| Sharpe Ratio 12m | 0.02 |
| Alpha | 2.84 |
| Beta | 0.679 |
| Volatility | 53.96% |
| Current Volume | 1920.6k |
| Average Volume 20d | 1542.1k |
| Stop Loss | 57.3 (-5%) |
| Signal | 1.06 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-606.3m TTM) > 0 and > 6% of Revenue (6% = 5.14m TTM) |
| FCFTA -0.36 (>2.0%) and ΔFCFTA -9.72pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 881.1% (prev 30.8k%; Δ -29.9kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.35 (>3.0%) and CFO -426.9m > Net Income -606.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.76 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (119.5m) change vs 12m ago 9.35% (target <= -2.0% for YES) |
| Gross Margin -227.0% (prev -10.4k%; Δ 10.2kpp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 6.24% (prev 0.21%; Δ 6.03pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -5.58 (EBITDA TTM -504.8m / Interest Expense TTM 92.1m) >= 6 (WARN >= 3) |
Altman Z'' -8.42
| (A) 0.62 = (Total Current Assets 886.5m - Total Current Liabilities 131.1m) / Total Assets 1.23b |
| (B) -2.45 = Retained Earnings (Balance) -3.00b / Total Assets 1.23b |
| warn (B) unusual magnitude: -2.45 — check mapping/units |
| (C) -0.37 = EBIT TTM -514.2m / Avg Total Assets 1.37b |
| (D) -1.88 = Book Value of Equity -3.00b / Total Liabilities 1.59b |
| Total Rating: -8.42 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 32.21
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -5.79% = -2.89 |
| 3. FCF Margin data missing |
| 4. Debt/Equity -2.33 = -2.50 |
| 5. Debt/Ebitda -1.24 = -2.50 |
| 6. ROIC - WACC (= -92.77)% = -12.50 |
| 7. RoE 309.2% = 2.50 |
| 8. Rev. Trend 29.94% = 2.25 |
| 9. EPS Trend 57.20% = 2.86 |
What is the price of CYTK shares?
Over the past week, the price has changed by -3.13%, over one month by -0.56%, over three months by +71.60% and over the past year by +8.65%.
Is Cytokinetics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CYTK is around 58.96 USD . This means that CYTK is currently overvalued and has a potential downside of -2.22%.
Is CYTK a buy, sell or hold?
- Strong Buy: 9
- Buy: 9
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CYTK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 75.8 | 25.8% |
| Analysts Target Price | 75.8 | 25.8% |
| ValueRay Target Price | 65.4 | 8.4% |
CYTK Fundamental Data Overview November 02, 2025
P/S = 88.7471
P/B = 60.3093
P/EG = -0.42
Beta = 0.679
Revenue TTM = 85.7m USD
EBIT TTM = -514.2m USD
EBITDA TTM = -504.8m USD
Long Term Debt = 713.0m USD (from longTermDebt, last quarter)
Short Term Debt = 34.0m USD (from shortTermDebt, last quarter)
Debt = 858.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 624.1m USD (from netDebt column, last quarter)
Enterprise Value = 7.61b USD (7.61b + Debt 858.1m - CCE 858.1m)
Interest Coverage Ratio = -5.58 (Ebit TTM -514.2m / Interest Expense TTM 92.1m)
FCF Yield = -5.79% (FCF TTM -440.5m / Enterprise Value 7.61b)
FCF Margin = -513.7% (FCF TTM -440.5m / Revenue TTM 85.7m)
Net Margin = -707.2% (Net Income TTM -606.3m / Revenue TTM 85.7m)
Gross Margin = -227.0% ((Revenue TTM 85.7m - Cost of Revenue TTM 280.4m) / Revenue TTM)
Gross Margin QoQ = 96.58% (prev -6223 %)
Tobins Q-Ratio = 6.21 (Enterprise Value 7.61b / Total Assets 1.23b)
Interest Expense / Debt = 2.83% (Interest Expense 24.3m / Debt 858.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -406.2m (EBIT -514.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.76 (Total Current Assets 886.5m / Total Current Liabilities 131.1m)
Debt / Equity = -2.33 (negative equity) (Debt 858.1m / totalStockholderEquity, last quarter -368.7m)
Debt / EBITDA = -1.24 (negative EBITDA) (Net Debt 624.1m / EBITDA -504.8m)
Debt / FCF = -1.42 (negative FCF - burning cash) (Net Debt 624.1m / FCF TTM -440.5m)
Total Stockholder Equity = -196.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -49.47% (Net Income -606.3m / Total Assets 1.23b)
RoE = 309.2% (negative equity) (Net Income TTM -606.3m / Total Stockholder Equity -196.1m)
RoCE = -99.47% (out of range, set to none) (EBIT -514.2m / Capital Employed (Equity -196.1m + L.T.Debt 713.0m))
RoIC = -84.88% (negative operating profit) (NOPAT -406.2m / Invested Capital 478.6m)
WACC = 7.88% (E(7.61b)/V(8.47b) * Re(8.52%) + D(858.1m)/V(8.47b) * Rd(2.83%) * (1-Tc(0.21)))
Discount Rate = 8.52% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.81%
Fair Price DCF = unknown (Cash Flow -440.5m)
EPS Correlation: 57.20 | EPS CAGR: 145.2% | SUE: 4.0 | # QB: 2
Revenue Correlation: 29.94 | Revenue CAGR: 229.5% | SUE: 4.0 | # QB: 1
Additional Sources for CYTK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle